IDEAYA Biosciences (IDYA) Financials: History & Chart

IDEAYA Biosciences, Inc.(IDYA)

Biotechnology · South San Francisco, CA

$36.63-1.43 (-3.76%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.

South San Francisco, CA

145 employees

www.ideayabio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Yujiro S. Hata

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	234.13M	8.86M	6.56M	10.88M	207.83M	0.00	0.00	7.00M	0.00
Cost of Goods Sold	265.32M	0.00	95.73M	86.60M	82.99M	74.23M	70.89M	643K	1.01M
Gross Profit	-31.19M	8.86M	-89.17M	-75.72M	124.84M	-74.23M	-70.89M	6.36M	-1.01M
Gross Profit Margin	-13.3%	100.0%	-1359.2%	-696.2%	60.1%	N/A	N/A	90.8%	N/A
Total Operating Expenses	185.76M	131.15M	19.38M	18.85M	16.39M	14.58M	13.50M	150.50M	65.88M
Research & Development	374.01M	108.69M	95.73M	86.60M	82.99M	74.23M	70.89M	140.18M	57.15M
Selling, General & Administrative	77.07M	22.46M	19.38M	18.85M	16.39M	14.58M	13.50M	10.31M	8.73M
Operating Income (EBIT)	-216.95M	-122.29M	-108.54M	-94.57M	108.45M	-88.81M	-84.39M	-144.14M	-66.89M
Operating Margin	-92.7%	-1380.7%	-1654.6%	-869.5%	52.2%	N/A	N/A	-2059.1%	N/A
Income Before Tax (EBT)	-175.02M	-112.45M	-98.54M	-83.27M	119.24M	-77.49M	-72.18M	-130.31M	-51.82M
Interest Income	41.93M	9.84M	10.01M	11.30M	10.79M	11.31M	12.21M	13.83M	15.07M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	41.93M	9.84M	10.01M	11.30M	10.79M	11.31M	12.21M	13.83M	15.07M
Net Income	-175.02M	-112.45M	-98.54M	-83.27M	119.24M	-77.49M	-72.18M	-130.31M	-51.82M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-74.8%	-1269.6%	-1502.1%	-765.7%	57.4%	N/A	N/A	-1861.6%	N/A
EBITDA	-212.46M	-121.17M	-107.40M	-93.37M	109.48M	-87.57M	-83.26M	-143.50M	-65.88M
EBITDA Margin	-90.7%	-1368.1%	-1637.2%	-858.5%	52.7%	N/A	N/A	-2049.9%	N/A
Depreciation & Amortization	4.49M	1.12M	1.14M	1.20M	1.03M	1.23M	1.13M	643K	1.01M
EPS Basic	-1.92	-1.22	-1.11	-0.94	1.35	-0.88	-0.82	-1.49	-0.60
EPS Diluted	-1.94	-1.22	-1.11	-0.94	1.33	-0.88	-0.82	-1.49	-0.60
Weighted Average Basic Shares	92.06M	92.06M	88.70M	88.58M	89.66M	88.47M	88.36M	87.34M	86.19M
Weighted Average Diluted Shares	92.06M	92.06M	88.70M	88.58M	89.69M	88.47M	88.36M	87.34M	86.19M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	218.71M	7.00M	23.39M	50.93M	27.94M	19.54M	0.00	0.00
Cost of Goods Sold	314.70M	3.83M	4.01M	2.10M	1.73M	1.38M	1.25M	886K
Gross Profit	-95.99M	3.17M	19.38M	48.83M	26.22M	18.16M	-1.25M	-886K
Gross Profit Margin	-43.9%	45.2%	82.9%	95.9%	93.8%	92.9%	N/A	N/A
Total Operating Expenses	63.32M	330.14M	153.81M	111.33M	76.48M	53.50M	43.03M	35.53M
Research & Development	314.70M	294.67M	129.51M	89.54M	58.16M	39.70M	34.32M	31.75M
Selling, General & Administrative	63.32M	35.47M	24.30M	21.80M	18.33M	13.80M	8.71M	3.78M
Operating Income (EBIT)	-159.31M	-326.98M	-134.43M	-62.50M	-50.27M	-35.34M	-44.27M	-36.42M
Operating Margin	-72.8%	-4671.1%	-574.9%	-122.7%	-179.9%	-180.9%	N/A	N/A
Income Before Tax (EBT)	-113.70M	-274.48M	-112.96M	-58.66M	-49.76M	-34.49M	-41.98M	-34.35M
Interest Income	45.62M	52.50M	21.47M	3.85M	506K	849K	2.29M	1.99M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	45.62M	52.50M	21.47M	3.85M	506K	849K	2.30M	2.07M
Net Income	-113.70M	-274.48M	-112.96M	-58.66M	-49.76M	-34.49M	-41.98M	-34.35M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-52.0%	-3921.1%	-483.0%	-115.2%	-178.1%	-176.6%	N/A	N/A
EBITDA	-154.72M	-323.14M	-130.42M	-60.40M	-48.54M	-33.96M	-43.03M	-35.53M
EBITDA Margin	-70.7%	-4616.3%	-557.7%	-118.6%	-173.7%	-173.8%	N/A	N/A
Depreciation & Amortization	4.59M	3.83M	4.01M	2.10M	1.73M	1.38M	1.25M	886K
EPS Basic	-1.28	-3.36	-1.96	-1.42	-1.41	-1.31	-1.90	-2.41
EPS Diluted	-1.28	-3.36	-1.96	-1.42	-1.41	-1.31	-1.90	-2.41
Weighted Average Basic Shares	88.49M	81.68M	57.52M	41.44M	35.25M	24.72M	20.23M	14.24M
Weighted Average Diluted Shares	88.49M	81.68M	57.52M	41.44M	35.25M	24.72M	20.23M	14.24M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.